Table 1:

Demographic characteristics of the sample

	Overall Sample (N=27)	Aβ negative (N=22)	Aβ positive (N=5)
Age (y)	67.9 (3.9)	67.3 (4.1)	70.8 (1.5)
Sex (% female)	55.6% (N=15)	50.0% (N=11)	80.0% (N=4)
Education (y)	15.5 (2.3)	15.4 (2.0)	16.2 (3.5)
WMH volume (ml)	0.9 (1.2)	1.0 (1.3)	0.5 (0.8)
MMSE	29.4 (0.8)	29.5 (0.7)	29.2 (1.1)
MADRS, Baseline	24.9 (5.4)	24.7 (5.9)	26.0 (2.5)
MADRS, Phase 1 End	10.0 (9.7)	8.0 (9.3)	18.6 (7.0)
Phase 1 Remitted	70.4% (N=19)	81.8% (N=18)	20% (N=1)
Phase 1 Dose (mg)	17.8 (4.24)	17.7 (4.3)	18.0 (4.5)
	(N=8)	(N=4)	(N=4)
MADRS, Phase 2 End	19.0 (10.3)	20.8 (14.5)	16.8 (5.4)
Phase 2 Dose (mg)	318.7 (96.13)	262.5 (75.0)	375.0 (86.6)

Continuous measures presented as mean (standard deviation) and categorical variables presented as % (number). Phase 1 dose calculated on number of pills as participants received either escitalopram or matching placebo. Phase 2 involved open-label bupropion administration.

CIRS = Cumulative Illness Rating Score; MADRS = Montgomery Asberg Depression Rating Scale; mg = milligrams; ml = milliliters; MMSE = Mini-Mental State Exam; WMH = white matter hyperintensity